Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
A Study of Ipilimumab, Cabozantinib and Nivolumab in Rare Genitourinary Tumors (A031702) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study of Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil/Leucovorin versus nab-paclitaxel plus Gemcitabine in subjects who have not previously recevied chemotherapy for metastatic adenocarcinoma of the pancreas (D-US-60010-001) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study of MGA271 in Combination with pembrolizumab and in combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and other cancers (CP-MGA271-03) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study of MGA271 in Combination with pembrolizumab and in combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and other cancers (CP-MGA271-03) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study of MGA271 in Combination with pembrolizumab and in combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and other cancers (CP-MGA271-03) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study of MGA271 in Combination with pembrolizumab and in combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and other cancers (CP-MGA271-03) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study of MGA271 in Combination with pembrolizumab and in combination with MGA012 in Patients with Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and other cancers (CP-MGA271-03) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Neoadjuvant Chemotherapy Alone vs Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab+BMS986205 Followed by Post Surgery Therapy with Nivolumab or Nivolumab+BMS986205 in Pts with Muscle Invasive Bladder CA (18095) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of NKTR-262 in Combination with NKTR-214 and with NKTR-214 Plus Nivolumab In Patients with Locally Advanced or Metastatic Solid Tumors of Urothelial or Renal Origin (REVEAL)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Osimertinib in Advanced NonSmall Cell Lung Cancer Patients with Exon20 Mutations in EGFR (EA5162) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Pembrolizumab + Olaparib vs Abiraterone or Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (MK7339-010) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Pembrolizumab and Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary (GY016) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study of PF06821497 in the treatment of adult patients with relapsed/refractory small cell lung cancer, castration resistant prostate cancer, and follicular lymphoma (C2321001) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study of PF06821497 in the treatment of adult patients with relapsed/refractory small cell lung cancer, castration resistant prostate cancer, and follicular lymphoma (C2321001) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study of PF06821497 in the treatment of adult patients with relapsed/refractory small cell lung cancer, castration resistant prostate cancer, and follicular lymphoma (C2321001) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of REGN5678 with Cemiplimab in Patients with Metastatic Castration Resistant Prostate Cancer (R5678-ONC-1879) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Regorafenib and Anti-PD-1 in Patients with Microsatellite Stable Colorectal Cancer (19096) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of Sitravatinib in Combination with Nivolumab vs Docetaxel in Patients with Advanced Nonsquamous Nonsmall Cell Lung Cancer with Disease Progression on or after Platinum Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy(MRT516005) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study of the Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (MT-3724NHL001)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer (GOG-3029)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study Testing the Addition of the Antibody Atezolizumab to Chemotherapy with Liposomal Doxorubicin and Bevacizumab in Recurrent Ovarian Cancer (GY009)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate Ribociclib in Combination with NonSteroidal Aromatase Inhibitor for the Treatment of Women with Advanced Breast Cancer Who have Received No Prior Therapy (19004) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A study to evaluate subcutaneous Daratumumab in combination with stafnard mutliple myeloma treatment regimens (54767414MMY2040) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-Small Cell Lung Cancer and Subjects with Metastatic Melanoma (APX005M-002) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A treatment protocol of Tucatinib in combination with Capecitabine and Trustuzumab in patients with previously treated unresectable locally advanced or metastatic HER2+ breast carcinoma (SGNTUC-021)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members